光学前臨床イメージングの世界市場

光学前臨床イメージングの世界市場は2030年までに9億3,690万米ドルに達する見込み

2023年に6億2,740万米ドルと推定される光学前臨床イメージングの世界市場は、2030年には9億3,690万米ドルに達し、分析期間2023-2030年のCAGRは5.9%で成長すると予測されます。本レポートで分析したセグメントの1つである生物発光／蛍光イメージングシステムは、CAGR 7.0％を記録し、分析期間終了までに5億3,690万米ドルに達すると予測されます。スタンドアロン蛍光イメージングシステム分野の成長率は、分析期間中CAGR 5.0％と推定されています。

米国市場は1億6,400万米ドルと推定、中国はCAGR9.2％で成長すると予測

米国の光学前臨床イメージング市場は、2023年に1億6,400万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR 9.2%を牽引し、2030年までに2億2,070万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.5％と4.7％と予測されています。欧州では、ドイツがCAGR 4.3%で成長すると予測されています。

世界の光学前臨床イメージング市場- 主要動向と促進要因のまとめ

光学前臨床イメージングはバイオメディカル調査をどう変えたか？

光学前臨床イメージングは、生物医学研究において革新的なツールとして登場し、科学者たちが生きた動物モデルの細胞や分子のプロセスを、かつてないほど詳細に可視化することを可能にしました。従来、研究者は病気の進行や治療効果を観察するために侵襲的な方法に頼っていたが、光学イメージング技術の進歩は、非侵襲的でリアルタイムの洞察を提供することで、前臨床研究に革命をもたらしました。蛍光や生物発光イメージングのような技術により、研究者は細胞やサブセルレベルでの生物学的変化をモニターできるようになり、複雑な生物学的メカニズムのより深い理解が容易になりました。この能力はがん研究において特に価値があり、光イメージングによって、何度も侵襲的な処置をすることなく、腫瘍の成長、転移、治療に対する反応を追跡することができます。研究者が同じ被験者について長期的な調査を行うことを可能にすることで、光イメージングは実験に必要な動物の数を最小限に抑え、生物医学研究における倫理的配慮に沿う。

がん研究の強化に加え、光学前臨床イメージングは免疫学、神経科学、感染症の研究を発展させてきました。免疫細胞の挙動や病原体と宿主の相互作用をリアルタイムで可視化する能力は、新たな治療法の発見につながる重要なデータを提供します。例えば、蛍光イメージングでは、感染症や腫瘍に反応する免疫細胞を追跡することができ、治療成績を向上させるために免疫反応をどのように調節できるかについての洞察を得ることができます。同様に、光イメージング技術は神経科学研究において、神経活動や脳機能のモニタリングに役立っています。疾患モデルにおけるニューロンの伝達や変性の様子を可視化することで、研究者はアルツハイマー病やパーキンソン病などの神経変性疾患の理解を深め、標的治療への道を開くことができます。このように、光学前臨床イメージングは、現代生物医学研究の最前線に位置し、さまざまな病態の理解を深めるために不可欠なツールとしての地位を確立しています。

さらに、光学イメージングとMRIやCTなどの他のイメージング技術を組み合わせたマルチモーダルイメージングシステムの開発により、前臨床研究の能力はさらに向上しています。これらのシステムは、生物学的洞察の精度と深度を高める補完的データを提供します。例えば、光イメージングが特定のバイオマーカーを検出する高い感度を提供する一方で、CTやMRIはそれらの所見を被験者の解剖学的枠組みの中で文脈づける構造的情報を追加します。このように機能的データと解剖学的データを統合することで、研究者は疾患の進行や治療への影響について、より包括的なイメージを構築することができます。マルチモーダルイメージングにより、光学前臨床イメージングは新たな領域へと踏み出し、前臨床の知見と臨床応用とのギャップを埋めることを目的としたトランスレーショナルリサーチにおいて、極めて重要な技術としての役割を確固たるものにしています。

オプティカルイメージングが医薬品開発で好まれる理由とは？

光学前臨床イメージングは、製薬会社が医薬品候補の有効性、分布、安全性を生体内で高感度に評価することを可能にし、医薬品開発において好まれる技術となっています。この非侵襲的な技術は、創薬や前臨床試験において、より迅速で費用対効果の高い方法を提供し、新しい治療法を実験室から臨床試験に持ち込むまでの時間を大幅に短縮します。蛍光・生物発光イメージングでは、薬物や生物学的マーカーに特定の蛍光プローブや発光プローブをタグ付けし、標的細胞やタンパク質と相互作用する際に発光させています。これらのシグナルは、薬物が特定の生物学的標的とどのように相互作用するかについてのリアルタイム情報を提供し、治療効果の評価や潜在的な副作用の特定を容易にします。光イメージングにより、研究者は複数の薬剤候補を迅速にスクリーニングし、有望な化合物の選択を効率化し、コストのかかる臨床段階に移行する前に投与量やデリバリー方法を改良することができます。

さらに、薬物が体内をどのように移動し、どのような影響を与えるかを追跡する薬物動態学や薬力学の研究においても、光イメージングが役立っています。蛍光マーカーを用いることで、科学者は生体内での薬物の吸収・分布・代謝・排泄（ADME）過程を可視化することができます。このデータは、最適な投与レジメンを決定し、薬物の化学的特性がバイオアベイラビリティと有効性にどのように影響するかを理解するために不可欠です。光学イメージングのリアルタイムフィードバックは、正確なターゲティングとモニタリングを必要とすることが多い抗体や遺伝子治療などの生物製剤の挙動を理解する上で特に価値があります。さらに、オプティカルイメージングは、体内の特定部位における薬物の生体内分布を測定することができ、研究者は、薬物が毒性につながる可能性のある非標的臓器に蓄積することなく、意図した標的に効果的に到達するかどうかを判断するのに役立ちます。このような詳細なレベルは、他のイメージング技術では達成することが困難であり、医薬品開発における光学イメージングのユニークな利点が強調されています。

光学前臨床イメージングは、がん、感染症、代謝性障害など、さまざまな疾患モデルに柔軟に対応できるため、トランスレーショナルリサーチにおいて不可欠なツールとなっています。光学イメージングにより、製薬会社は、研究対象の疾患に関連する特定のマーカーを発現する遺伝子組み換え生物を用いて、様々な病態モデルで薬剤候補の厳密な試験を実施することができます。例えば、代謝障害を研究する研究者は、光イメージングを用いてグルコース取り込みや脂質代謝の変化をリアルタイムで観察することができ、新薬の治療効果に関する貴重な洞察を得ることができます。このような疾患モデルや研究目的に対する光イメージングの適応性は、研究者が効果的で安全な治療法の発見を加速させるデータ主導の意思決定を行えるようにし、研究開発パイプラインにおける光イメージングの重要な役割を強調しています。

光学前臨床イメージングはどのように精密医療を進めているのか？

個々の患者の特性に基づいて治療をカスタマイズすることを目的とする精密医療の分野は、光学前臨床イメージングの進歩から大きな恩恵を受けています。非常に詳細な分子および細胞に関する洞察を提供することで、光イメージングにより、研究者は疾患の根本的なメカニズムを個別化されたレベルで理解することができ、これは標的治療の開発に不可欠です。この能力は、腫瘍の不均一性により患者によって治療への反応が異なる腫瘍学において特に価値があります。光イメージングにより、研究者は生きたモデルで腫瘍の分子プロファイルを分析し、どの患者が特定の治療に反応するかを示すバイオマーカーを特定することができます。この精密さ主導のアプローチにより、治療計画のカスタマイズが可能になり、精密医療の中核的目的である不必要な副作用を最小限に抑えながら治療成果を最大化することができます。

光イメージングもまた、疾患感受性や治療効果に影響を与える遺伝的要因を理解する上で重要な役割を果たしています。例えば遺伝子編集研究では、蛍光マーカーを用いて遺伝子改変の影響をリアルタイムで追跡し、特定の遺伝子改変が病気の進行や薬効にどのような影響を及ぼすかを示すことができます。これにより、研究者は遺伝子治療の可能性を探り、CRISPRベースの治療の安全性と有効性を評価することができます。さらに、光イメージングによって特定の遺伝子変異が細胞経路にどのような影響を与えるかを可視化することができるので、科学者は希少疾患や複雑な疾患の潜在的治療ターゲットを特定することができます。このレベルの洞察は、患者固有の遺伝子プロファイルと疾患の特徴に基づいて治療を調整することを目標とする精密医療を進める上で不可欠です。

免疫療法の領域では、光学前臨床イメージングが、腫瘍と闘うために身体の免疫系を利用する個別化がん治療を開発する新たな可能性を切り開いた。生物発光イメージングのような光学的イメージング技術により、研究者は免疫細胞と腫瘍との相互作用を観察することができ、生体内で免疫療法がどのように行われるかについての貴重なデータを得ることができます。免疫細胞の動きや活動を追跡することによって、研究者たちは、どのタイプの免疫細胞が特定の腫瘍タイプを標的とするのに最も効果的かを特定し、腫瘍がどのように免疫応答を回避するかをモニターすることができます。この情報は、個々の患者の免疫プロファイルに合わせたより効果的な免疫療法をデザインするために極めて重要であり、プレシジョン・メディシンの目標に合致します。複雑な生物学的メカニズムを明らかにする能力を通じて、光学前臨床イメージングは個別化治療の開発を進めるだけでなく、遺伝、免疫、疾患の間の複雑な相互作用の解明にも貢献しています。

何が光学前臨床イメージング市場の成長を促進しているのか？

光学前臨床イメージング市場の成長は、画像技術の進歩、創薬への投資の増加、精密医療の台頭など、いくつかの要因によってもたらされています。前臨床研究において、より正確で、非侵襲的で、費用対効果の高いイメージング技術が求められていることが、光学イメージングシステム、特に蛍光、生物発光、マルチモーダルイメージングにおける技術革新に拍車をかけています。これらの技術により、研究者は疾患メカニズム、薬効、バイオマーカー発現に関する非常に詳細な研究を実施することができ、学術研究と医薬品開発の両方を推進する重要なデータを提供することができます。光学イメージングの利用しやすさと感度の高さ、そしてリアルタイムのフィードバックを提供する能力は、医薬品開発がより複雑でデータ駆動型になるにつれて拡大し続ける前臨床研究のための貴重なツールとなっています。このような創薬や疾患研究における高度なイメージングソリューションのニーズは、光学前臨床イメージング市場を前進させる重要な要因です。

もう一つの重要な促進要因は、精密医療がますます重視されるようになっていることであり、光学前臨床イメージングは個々の患者プロファイルに基づく標的療法の開発に不可欠です。精密医療は分子レベルで病気を理解しようとするものであるため、光イメージングが病気モデル内の細胞や遺伝的プロセスを調査するのに必要なツールを提供し、研究者がバイオマーカーを同定し、それに応じて治療法を調整することを可能にします。生きたモデルでバイオマーカーの活性を可視化し定量化する能力は、精密医療の目標に合致しており、前臨床の知見を個別化治療に結びつけるために光イメージングが不可欠となっています。研究と臨床の両方における精密医療への継続的なシフトが、光イメージング技術の成長に拍車をかけています。研究者は、個人レベルでのデータ収集と分析を容易にするツールを必要としており、最終的には、より効果的で個別化された治療の選択肢を生み出すのに役立っています。

さらに、前臨床研究における低侵襲技術への注目の高まりは、動物の使用量を減らしデータの一貫性を向上させた縦断的研究を可能にするため、光イメージングの採用を促進しています。光学イメージングの非侵襲的な性質は、同じ被験者で繰り返し測定を行うのに特に価値があり、大規模なサンプルサイズの必要性を減らし、動物研究における倫理基準に合致しています。製薬会社や学術機関は、前臨床試験を最適化するために、光学イメージングを採用するケースが増えています。倫理的な研究慣行への継続的な支援と効率的な医薬品開発パイプラインの必要性により、光学前臨床イメージングソリューションの需要は着実に増加し、生物医学研究の進歩を支え、光イメージング市場の成長を促進すると予想されます。

セグメント

モダリティ（生物発光／蛍光イメージングシステム、スタンドアロン蛍光イメージングシステム、光学＋X線／光学＋CT）、エンドユーザー（製薬／バイオテクノロジー企業、研究機関、その他のエンドユーザー）

調査対象企業の例（全42件）

• BioTek Instruments, Inc.
• Bruker Corporation
• Fujifilm Holdings America Corporation
• Fujifilm Holdings Corporation
• Magnetic Insight, Inc.
• MBF Bioscience
• Mediso Ltd.
• MILabs B.V.
• Miltenyi Biotec
• MR Solutions
• PerkinElmer, Inc.
• TriFoil Imaging
• UVP
• Vieworks Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Optical Preclinical Imaging Market to Reach US$936.9 Million by 2030

The global market for Optical Preclinical Imaging estimated at US$627.4 Million in the year 2023, is expected to reach US$936.9 Million by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030. Bioluminescence / Fluorescence Imaging Systems, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$536.9 Million by the end of the analysis period. Growth in the Standalone Fluorescence Imaging Systems segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$164.0 Million While China is Forecast to Grow at 9.2% CAGR

The Optical Preclinical Imaging market in the U.S. is estimated at US$164.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$220.7 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Optical Preclinical Imaging Market - Key Trends & Drivers Summarized

How Has Optical Preclinical Imaging Transformed Biomedical Research?

Optical preclinical imaging has emerged as a transformative tool in biomedical research, enabling scientists to visualize cellular and molecular processes in live animal models with unprecedented detail. Traditionally, researchers relied on invasive methods to observe disease progression and treatment efficacy, but advancements in optical imaging technology have revolutionized preclinical studies by offering non-invasive, real-time insights. Techniques such as fluorescence and bioluminescence imaging allow researchers to monitor biological changes at cellular and subcellular levels, facilitating a deeper understanding of complex biological mechanisms. This capability is especially valuable in cancer research, where optical imaging can track tumor growth, metastasis, and responses to therapies without the need for multiple invasive procedures. By allowing researchers to conduct longitudinal studies on the same subject, optical imaging minimizes the number of animals required for experiments, which aligns with ethical considerations in biomedical research.

In addition to enhancing cancer research, optical preclinical imaging has advanced studies in immunology, neuroscience, and infectious diseases. The ability to visualize immune cell behavior and pathogen-host interactions in real-time provides critical data that can drive new therapeutic discoveries. For example, fluorescence imaging can track immune cells as they respond to infections or tumors, providing insights into how immune responses could be modulated to improve treatment outcomes. Similarly, optical imaging techniques are instrumental in neuroscience research, where they are used to monitor neural activity and brain function. By visualizing how neurons communicate or degenerate in disease models, researchers can better understand neurodegenerative diseases like Alzheimer’s and Parkinson’s, paving the way for targeted therapies. Thus, optical preclinical imaging has established itself as an indispensable tool for advancing our understanding of a wide array of medical conditions, positioning it at the forefront of modern biomedical research.

Moreover, the development of multimodal imaging systems, which combine optical imaging with other imaging techniques such as MRI or CT, has further extended the capabilities of preclinical studies. These systems provide complementary data that enhance the accuracy and depth of biological insights. For instance, while optical imaging offers high sensitivity for detecting specific biomarkers, CT and MRI add structural information that contextualizes those findings within the anatomical framework of the subject. This integration of functional and anatomical data enables researchers to build a more comprehensive picture of disease progression and therapeutic impact. With multimodal imaging, optical preclinical imaging is entering new realms of sophistication, solidifying its role as a pivotal technology for translational research aimed at bridging the gap between preclinical findings and clinical applications.

What Makes Optical Imaging a Preferred Technique in Drug Development?

Optical preclinical imaging has become a preferred technique in drug development, allowing pharmaceutical companies to evaluate the efficacy, distribution, and safety of drug candidates in vivo with high sensitivity. This non-invasive technique offers a faster and more cost-effective method for drug discovery and preclinical testing, significantly reducing the time it takes to bring new treatments from the laboratory to clinical trials. In fluorescence and bioluminescence imaging, drugs or biological markers are tagged with specific fluorescent or luminescent probes that emit light when interacting with target cells or proteins. These signals provide real-time information on how drugs interact with specific biological targets, making it easier to assess therapeutic effectiveness and identify potential side effects. With optical imaging, researchers can quickly screen multiple drug candidates, streamline the selection of promising compounds, and refine dosage and delivery methods before moving into costly clinical stages.

Furthermore, optical imaging is instrumental in pharmacokinetics and pharmacodynamics studies, which track how drugs move through and affect the body. By using fluorescent markers, scientists can visualize drug absorption, distribution, metabolism, and excretion (ADME) processes within living organisms. This data is essential for determining optimal dosing regimens and understanding how a drug's chemical properties impact its bioavailability and efficacy. Optical imaging's real-time feedback is especially valuable in understanding the behavior of biologics, such as antibodies and gene therapies, which often require precise targeting and monitoring. In addition, optical imaging can measure drug biodistribution at specific sites within the body, helping researchers determine if a drug effectively reaches its intended target without accumulating in non-targeted organs, which could lead to toxicity. This level of detail is difficult to achieve with other imaging techniques, highlighting the unique advantages of optical imaging in drug development.

The flexibility of optical preclinical imaging to work across various disease models, including cancer, infectious diseases, and metabolic disorders, has made it an essential tool in translational research. Optical imaging enables pharmaceutical companies to conduct rigorous testing of drug candidates in a wide range of pathological models, often using genetically modified organisms that express specific markers relevant to the disease being studied. For instance, researchers studying metabolic disorders can use optical imaging to observe changes in glucose uptake or lipid metabolism in real-time, providing valuable insights into the therapeutic effects of new drugs. This adaptability of optical imaging across disease models and research goals underscores its vital role in the drug development pipeline, empowering researchers to make data-driven decisions that accelerate the discovery of effective and safe treatments.

How Is Optical Preclinical Imaging Advancing Precision Medicine?

The field of precision medicine, which aims to customize treatments based on individual patient characteristics, has greatly benefited from advancements in optical preclinical imaging. By providing highly detailed molecular and cellular insights, optical imaging enables researchers to understand the underlying mechanisms of diseases at a personalized level, which is essential for developing targeted therapies. This capability is particularly valuable in oncology, where the heterogeneity of tumors means that different patients respond to treatments differently. With optical imaging, researchers can analyze the molecular profile of tumors in live models, identifying biomarkers that indicate which patients may respond to specific therapies. This precision-driven approach allows for the customization of treatment plans, maximizing therapeutic outcomes while minimizing unnecessary side effects, which is the core objective of precision medicine.

Optical imaging also plays a critical role in understanding genetic factors that influence disease susceptibility and treatment responses. In gene-editing studies, for example, fluorescent markers can be used to track the effects of gene modifications in real-time, showing how certain genetic alterations impact disease progression or drug efficacy. This allows researchers to explore potential gene therapies and assess the safety and effectiveness of CRISPR-based treatments. Additionally, optical imaging can visualize how specific genetic mutations affect cellular pathways, enabling scientists to identify potential therapeutic targets for rare and complex diseases. This level of insight is essential for advancing precision medicine, where the goal is to tailor treatments based on a patient’s unique genetic profile and disease characteristics.

In the realm of immunotherapy, optical preclinical imaging has opened up new possibilities for developing personalized cancer treatments that harness the body’s immune system to fight tumors. Optical imaging techniques, such as bioluminescence imaging, allow researchers to observe immune cell interactions with tumors, providing valuable data on how immunotherapies perform within a living organism. By tracking the movement and activity of immune cells, researchers can identify which types of immune cells are most effective in targeting specific tumor types and monitor how tumors evade immune responses. This information is crucial for designing more effective immunotherapies tailored to individual patients' immune profiles, aligning with the goals of precision medicine. Through its ability to reveal intricate biological mechanisms, optical preclinical imaging is not only advancing the development of personalized treatments but also helping to unravel the complex interactions between genetics, immunity, and disease.

What Is Fueling the Growth in the Optical Preclinical Imaging Market?

The growth in the optical preclinical imaging market is driven by several factors, including advancements in imaging technology, increased investment in drug discovery, and the rise of precision medicine. The demand for more accurate, non-invasive, and cost-effective imaging techniques in preclinical studies has fueled innovation in optical imaging systems, particularly in fluorescence, bioluminescence, and multimodal imaging. These technologies allow researchers to conduct highly detailed studies on disease mechanisms, drug efficacy, and biomarker expression, providing critical data that drive both academic research and pharmaceutical development. The accessibility and sensitivity of optical imaging, combined with its ability to deliver real-time feedback, make it a valuable tool for preclinical studies, which continue to expand as drug development becomes more complex and data-driven. This need for sophisticated imaging solutions in drug discovery and disease research is a key factor propelling the optical preclinical imaging market forward.

Another significant driver is the increasing emphasis on precision medicine, where optical preclinical imaging is essential for developing targeted therapies based on individual patient profiles. As precision medicine seeks to understand diseases at a molecular level, optical imaging provides the tools necessary to study cellular and genetic processes within disease models, enabling researchers to identify biomarkers and tailor therapies accordingly. The ability to visualize and quantify biomarker activity in live models aligns with the goals of precision medicine, making optical imaging indispensable for translating preclinical findings into personalized treatments. The ongoing shift toward precision medicine in both research and clinical practice has spurred growth in optical imaging technologies, as researchers require tools that can facilitate data collection and analysis on an individual level, ultimately helping to create more effective and personalized treatment options.

Furthermore, the growing focus on minimally invasive techniques in preclinical research is driving the adoption of optical imaging, as it allows for longitudinal studies with reduced animal usage and improved data consistency. Optical imaging’s non-invasive nature is particularly valuable for conducting repeated measures on the same subject, reducing the need for large sample sizes and aligning with ethical standards in animal research. Pharmaceutical companies and academic institutions are increasingly adopting these methods to optimize their preclinical studies, as optical imaging reduces costs and enhances experimental efficiency. With continued support for ethical research practices and the need for efficient drug development pipelines, the demand for optical preclinical imaging solutions is expected to rise steadily, supporting advancements in biomedical research and driving the growth of the optical imaging market.

SCOPE OF STUDY:

The report analyzes the Optical Preclinical Imaging market in terms of US$ Thousand by the following End-Use; Modality, and Geographic Regions/Countries:

Segments:

Modality (Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems, Optical + X-Ray / Optical + CT); End-Use (Pharma & Biotech Companies, Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• BioTek Instruments, Inc.
• Bruker Corporation
• Fujifilm Holdings America Corporation
• Fujifilm Holdings Corporation
• Magnetic Insight, Inc.
• MBF Bioscience
• Mediso Ltd.
• MILabs B.V.
• Miltenyi Biotec
• MR Solutions
• PerkinElmer, Inc.
• TriFoil Imaging
• UVP
• Vieworks Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Global Economic Update
  • Optical Preclinical Imaging - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advancements in Molecular Imaging Techniques Drive Adoption of Optical Preclinical Imaging
  • Increased R&D Expenditure in Biotechnology Propels Demand for Preclinical Imaging
  • Rising Demand for Cancer Research Boosts the Need for Optical Imaging
  • Technological Advancements in Fluorescence Imaging Sets the Stage for Market Growth
  • Government Funding for Biomedical Research Strengthens the Optical Imaging Market
  • Expanding Drug Discovery Programs Drive Growth in Optical Preclinical Imaging
  • Innovations in Imaging Agents Propel Demand for Optical Imaging
  • Advancements in 3D Imaging Drive Demand for Optical Preclinical Solutions
  • Increasing Use of Imaging in Stem Cell Research Strengthens Market Growth
  • Use of Optical Imaging for Neurodegenerative Disease Research Expands Opportunities
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 10: World Optical Preclinical Imaging Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Optical Preclinical Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Bioluminescence / Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Bioluminescence / Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Bioluminescence / Fluorescence Imaging Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Standalone Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Standalone Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Standalone Fluorescence Imaging Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Optical + X-Ray / Optical + CT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Optical + X-Ray / Optical + CT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Optical + X-Ray / Optical + CT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: Canada 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• JAPAN
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Japan 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• CHINA
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 41: China Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: China 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• EUROPE
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Europe 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Optical Preclinical Imaging by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• FRANCE
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: France 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 59: France Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• GERMANY
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: Germany 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: Italy 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: UK 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 77: UK Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 80: Spain Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Spain Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: Spain 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 86: Russia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Russia Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: Russia 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Rest of Europe Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Rest of Europe 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Optical Preclinical Imaging by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 107: Australia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Australia Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 109: Australia 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 110: Australia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Australia Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 112: Australia 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• INDIA
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 113: India Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 114: India Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 115: India 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 116: India Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 117: India Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 118: India 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 119: South Korea Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 120: South Korea Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 121: South Korea 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 122: South Korea Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 123: South Korea Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 124: South Korea 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Rest of Asia-Pacific Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Rest of Asia-Pacific Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 131: Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Latin America Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 133: Latin America 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Optical Preclinical Imaging by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 136: Latin America 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 140: Argentina Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Argentina Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 142: Argentina 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 143: Argentina Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Argentina Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 145: Argentina 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 146: Brazil Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Brazil Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 148: Brazil 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 149: Brazil Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Brazil Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 151: Brazil 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 152: Mexico Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Mexico Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 154: Mexico 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 155: Mexico Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Mexico Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 157: Mexico 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Rest of Latin America Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 160: Rest of Latin America 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Rest of Latin America Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 163: Rest of Latin America 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 164: Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Middle East Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 166: Middle East 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Optical Preclinical Imaging by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 169: Middle East 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 173: Iran Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Iran Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 175: Iran 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 176: Iran Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Iran Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 178: Iran 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 179: Israel Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Israel Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 181: Israel 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 182: Israel Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Israel Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 184: Israel 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Saudi Arabia Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 187: Saudi Arabia 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Saudi Arabia Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 190: Saudi Arabia 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 191: UAE Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 192: UAE Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 193: UAE 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 194: UAE Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 195: UAE Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 196: UAE 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Rest of Middle East Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 199: Rest of Middle East 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Rest of Middle East Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 202: Rest of Middle East 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
• AFRICA
  • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 203: Africa Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Africa Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 205: Africa 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
  • TABLE 206: Africa Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Africa Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 208: Africa 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030

IV. COMPETITION